24 volunteers will take part in the trials of the PowderJect system following the success of an earlier study.
In the new trial volunteers will receive three doses of vaccine under two immunization schedules.
|The injection system uses microscopic solid particles, accelerated to high speed down a nozzle into the skin.|
Researchers will test antibody and cellular immune responses and the extent of the immune memory elicited by the drug.
The injection system uses microscopic solid particles, which are accelerated to high speed down a special nozzle into the outer layers of the skin. PowderJect, of Oxford, England, has developed the vaccine in collaboration with GlaxoSmithKline.
PowderJect said an earlier clinical trial had demonstrated that the DNA vaccine induced protective levels of antibodies in all volunteers.
Dr Paul Drayson, chief executive of PowderJect Pharmaceuticals, said, "The start of this study marks the beginning of our program to develop a further effective treatment for hepatitis B."
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com